CD Skripsi

Efek Bortezomib Terhadap Kadar 8-Hydroxy-2'-Deoxyguanosine (8-Ohdg) Serum Pada Tikus Model Aterosklerosis

---

Proteasomes are large multisubunite proteases that play a role in the largest multicellular protein degradation complex. Proteasomes play a role in cell cycle, apoptosis, cell division, growth, transcription regulation and intracellular signaling, this process plays an important role in the formation of atherosclerosis. Bortezomib is a proteasome inhibitor used in multiple myeloma therapy. Bortezomib plays a role in inhibiting proteasome activity. This study aimed to analyze the effects of bortezomib on 8-hydroxy-2’-deoxyguanosine (8-OHdG) level in the serum of atherosclerotic rats. The experimental study used 18 male Wistar strain rats that were divided into three groups named the control group (I), atherosclerosis group (II), and the atherosclerosis + bortezomib (III) group. Atherosclerosis induction was done by administering vitamin D3 (700,000 IU / kgBB) peroral by means of stomach intubation on the 1st day and atherogenic feed in the form of (cholesterol 2%, goat fat 5%, kolic acid 0.2%) for 4 days. Low dose bortezomib (50 μg/kgBW/day) was given twice that was on the 1st and 3rd days intraperitoneally. Measurement of levels 8-OHdG used ELISA method. The results showed that the average level of 8-OHdG was highest in the atherosclerosis group at 10.56317 and the lowest in the atherosclerosis + bortezomib group was 8.23767. The used of bortezomib resulted the decrease of 8-OHdG levels, even though it didn't show any significant statistical results.
Keywords : Bortezomib, atherosclerosis, 8-hydroxy-2’-deoxyguanosine

---

Ketersediaan

Informasi Detail

Judul Seri

-

No. Panggil

1808156130

Penerbit

Pekanbaru : Universitas Riau – KEDOKTERAN– PENDIDIKAN KEDOKTERAN., 2022

Deskripsi Fisik

-

Bahasa

Indonesia

ISBN/ISSN

-

Klasifikasi

1808156130

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

-

Subjek

PENDIDIKAN KEDOKTERAN

Info Detail Spesifik

-

Pernyataan Tanggungjawab

nadya

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar